EW
Edwards Lifesciences Corp
NYSE · Healthcare · Medical - Devices · US
$99.37
+4.39%Nov 2, 2026, 18:25 UTC
Edwards Lifesciences announced that its PASCAL system demonstrated superiority to medical therapy alone on the Edwards Lifesciences Corp’s six-month primary endpoint, with reduced tricuspid regurgitation and improved health status sustained through one year.
Source:Nov 2, 2026, 17:40 UTC
Edwards Lifesciences Corp announced that the Edwards Lifesciences Corp found TAVR superior to clinical surveillance for the primary composite endpoint of death or heart failure events at two years among moderate aortic stenosis patients with at-risk features.
Source:Oct 8, 2026, 23:59 UTC
The European Commission selected products from Edwards Lifesciences Corp and HighLife SAS as the first medical devices to undergo joint clinical assessment.
Source:Oct 7, 2026, 10:00 UTC
Edwards Lifesciences Corp plans to announce its operating results for the quarter ended September 30, 2026, after market close on November 4, 2026, and host a conference call that day at 5:00 p.m. ET.
Source:Oct 5, 2026, 10:00 UTC
Edwards Lifesciences announced it will host an investor event in conjunction with the TCT annual scientific symposium in San Diego on Nov. 2, 2026.
Source:Oct 1, 2026, 20:26 UTC
The U.S. Food and Drug Administration approved Edwards Lifesciences' AUTUS Size-Adjustable Valve, the first surgical pulmonary valve designed for pediatric patients with congenital heart disease.
Source:Sep 23, 2026, 08:15 UTC
China's National Medical Products Administration approved three additional valve-in-valve indications for Edwards Lifesciences' SAPIEN 3 transcatheter heart valve system, making it the first transcatheter heart valve in China with three valve-in-valve indications.
Source:Sep 11, 2026, 23:45 UTC
Daniel J. Lippis, CVP, TAVR at Edwards Lifesciences Corp, sold 619 shares of the company's common stock for $54,168 on September 11, 2026, and concurrently acquired 619 shares via employee stock option exercise at $72.68 per share.
Source:Sep 10, 2026, 21:49 UTC
The Centers for Medicare & Medicaid Services released a national coverage determination for transcatheter aortic valve replacement (TAVR), prompting a statement from Edwards Lifesciences.
Source:Aug 28, 2026, 20:20 UTC
Donald E. Bobo, Jr. retired as Corporate Vice President of Strategy and Corporate Development at Edwards Lifesciences Corp.
Aug 23, 2026, 08:30 UTC
EP Wealth Advisors LLC acquired a new position in Edwards Lifesciences Corporation by purchasing 37,702 shares valued at approximately $3,410,000, as disclosed in a recent SEC filing.
Source:Aug 22, 2026, 07:57 UTC
B. Metzler seel. Sohn & Co. AG acquired a new position of 41,753 shares in Edwards Lifesciences Corporation during the second quarter, valued at approximately $3,777,000.
Source:Aug 22, 2026, 07:11 UTC
Allworth Financial LP acquired a new position in Edwards Lifesciences Corporation, buying 16,600 shares valued at approximately $1,502,000 during the second quarter, as disclosed in a 13F filing.
Source:Aug 17, 2026, 08:33 UTC
Baxter Bros Inc. disclosed a new minority stake in Edwards Lifesciences Corporation, purchasing 39,184 shares valued at approximately $3.54 million during the undefined quarter.
Source:Jul 24, 2026, 00:30 UTC
The FTC secured $12 million in penalties from Edwards Lifesciences Corp. and Genesis MedTech Group Limited for failing to make a Hart-Scott-Rodino filing.
Source:Jul 23, 2026, 20:15 UTC
Edwards Lifesciences reported financial results for the second quarter ended June 30, 2026, with sales of $1.74 billion and EPS of $0.42.
Jul 16, 2026, 04:29 UTC
Jenscare Scientific's LuX-Valve Plus system completed the first patient implantations in the FDA-approved pivotal clinical trial in the United States.
Source: